p53 immunohistochemistry must be confirmed by TP53 next generation sequencing for accurate risk stratification of patients with mantle cell lymphoma

Leuk Lymphoma. 2022 Dec;63(14):3504-3507. doi: 10.1080/10428194.2022.2118529. Epub 2022 Sep 5.

Authors

James Nolan^{1

2}, Catherine Murphy¹, Kate Dinneen¹, Greg Lee¹, Elizabeth Higgins¹, Larry Bacon¹, David O'Brien¹, Richard Flavin^{3

4}, Fiona Quinn⁵, Elisabeth Vandenberghe^{1

2}

Affiliations

¹ Department of Haematology, St James' Hospital, Dublin 8, Ireland.
² Department of Haematology, Trinity College, Dublin 2, Ireland.
³ Department of Histopathology, St James' Hospital, Dublin 8, Ireland.
⁴ Department of Histopathology, Trinity College, Dublin 2, Ireland.
⁵ Cancer Molecular Diagnostics Laboratory, St James' Hospital, Dublin 8, Ireland.

PMID: 36059262
DOI: 10.1080/10428194.2022.2118529

No abstract available

MeSH terms

High-Throughput Nucleotide Sequencing
Humans
Immunohistochemistry
Lymphoma, Mantle-Cell* / diagnosis
Lymphoma, Mantle-Cell* / pathology
Mutation
Risk Assessment
Tumor Suppressor Protein p53 / genetics

Substances

TP53 protein, human
Tumor Suppressor Protein p53